1/5 Excited to share our @MsaouelLab clinical analysis of 135 patients with #RenalMedullaryCarcinoma treated MD Anderson Cancer Center over 20 years 👉sciencedirect.com/science/articl… #endRMC #rarecancers Kidney Cancer Chris Johnson Foundation Inc. RMC Alliance R.M.C. Inc Rare Cancer Research Foundation + Pattern.org The Renal Medullary Carcinoma Research Foundation KCCure

🎙️ Episode 13 is now available wherever you find your favourite podcasts! Watch the final part of our mini-series with Dr. Andrew Loblaw, where our hosts discuss how he manages post-operative treatment for #ProstateCancer: theviewongu.com @lalanimd @walliscjd

#TiNivo2 results are out —adding PD1 inhibitor nivolumab simply does not help after rechallenge /progression on prior immunotherapy. Time to follow level 1 evidence! PRNEWS Targeted Oncology OncLive.com KidneyCAN Kidney Cancer Uromigos Oncology Brothers —implications beyond renal cancer ?

In Episode 13, @lalanimd asks @drandrewloblaw how decision-making conversations about PSMA PET scans happen, and specifically how Multidisciplinary Cancer Conferences can and should factor in: theviewongu.com @walliscjd

1/ Results from #LITESPARK-005 are out NEJM! The phase 3 trial that led to HIF-2 inhibitor Belzutifan (BEL) U.S. FDA approval Dec 2023 in pretreated pts w/ #ccRCC. Presentation #ESMO24 @myEsmo Check it out: nejm.org/doi/full/10.10…

🎒✏️🍎Back to school & back to work! We are happy to share these ESMO - Eur. Oncology highlights with you so please be sure to plan your September! 🍂 ➡️For more info and to register > cua.org/event/33193 Wes Kassouf Aly-Khan Lalani

We are happy to present ESMO - Eur. Oncology highlights with you so please be sure to plan your September! For more info and to register > cua.org/event/33193 Wes Kassouf Aly-Khan Lalani

As we gear up for another conference season with #esmo24 happening soon, it’s a great time to listen in to the insights from Pavlos Msaouel on trial design and interpretation with us on The View on GU | with Lalani & Wallis Aly-Khan Lalani

My TOP 10 #GU ESMO - Eur. Oncology abstracts for #ESMO24 1/ 3

Paper out- TLX-250cdx as a tool to help patients with renal masses! also excited to have high risk postop staging protocol open too (Canine). UCLA Urology . Kidney Cancer KCCure KidneyCAN Kidney Cancer Canada YUO thelancet.com/journals/lanon… clinicaltrials.gov/study/NCT06447…

🆕 Immune checkpoint inhibitors are a first-line treatment for advanced renal cell carcinoma, but optimal treatment after progression is unknown. A study being presented at #ESMO24 supports that ICI rechallenge should be discouraged in this patient group: hubs.li/Q02PPz7S0

First presentation of ESMO - Eur. Oncology - addition of nivoluamb to tiovzanib does not improve outcomes following progression on immunotherapy; tivozanib with encouraging PFS of over 9 months when used second line - full data in The Lancet Toni Choueiri, MD Aly-Khan Lalani Dana-Farber Lank Center for Genitourinary Oncology

1/ Results from #TiNivo2 are out both @myEsmo #ESMO24 and The Lancet! Another phase 3 trial to assess the efficacy of immunotherapy rechallenge, comparing tivozanib + nivolumab vs. tivozanib monotherapy in patients w/ #RCC following an immune checkpoint inhibitor (ICI).

#ESMO24 Sunniforecast: kudos to team for this RP2 trial! - reaffirms ensuring access of typical ccRCC options for nccRCC pts, use in appropriate histologies - chromophobe ORR, findings by PDL1+ of interest - inertia for specific studies per molecularly driven subtypes ESMO - Eur. Oncology

Bravo! Agreeing with both of you, 100%. Adding: in many countries, health technology assessment will provide important guardrails re evidence-based sequencing, reducing likelihood of "all risk w no benefit", not to mention added #financialtoxicity #kidneycancer #HTA

AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or observation for 1 year. The pembrolizumab group had a median disease-free survival twice as long as the observation group. nej.md/4gh1b9D #ESMO24

Thank you Dr. Maria De Santis for this wonderful discussion of the 3 mini-oral abstracts presented this morning! Huge strides in #urothelial #bladder cancer and more on the way ESMO - Eur. Oncology #ESMO2024 Don’t miss today’s presidential by superstar Tom Powles TIME ! OncoAlert

Neoadjuvant chemotherapy plus durvalumab, followed by adjuvant durvalumab after cystectomy, led to event-free survival superior to that with neoadjuvant chemotherapy followed by cystectomy alone. Full NIAGARA trial results: nej.md/4gmAqk3 #ESMO24

The #ViewOnGU's @lalanimd & @walliscjd have arrived at the ESMO - Eur. Oncology conference in Barcelona! While in Spain, they will of course keep you all up to date on what they learn at the conference in all new episodes of the podcast! theviewongu.ca #ESMO24

Watch out for episodes coming soon summarizing all the top GU data including NIAGARA, TiNivo-2, SunRise-1, ARANOTE, SPLASH, AMBASSADOR, and many others Aly-Khan Lalani